Who are Ivermectin on Day 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral ivermectin, Ivermectin 400 µg/kg, Soolantra® Ivermectin cream 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivermectin-on-day-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ivermectin on Day 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin on Day 1 (Ivermectin on Day 1) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrocyclic lactone antiparasitic. Area: Infectious Disease / Parasitology.

phase 3 Macrocyclic lactone antiparasitic Glutamate-gated chloride channels (GluCl) Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Ivermectin on Day 1 (Ivermectin on Day 1) — Lihir Medical Centre. Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites, causing paralysis and death.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ivermectin on Day 1 TARGET	Ivermectin on Day 1	Lihir Medical Centre	phase 3	Macrocyclic lactone antiparasitic	Glutamate-gated chloride channels (GluCl)
Oral ivermectin	Oral ivermectin	University of Oxford	marketed	Macrocyclic lactone antiparasitic	Glutamate-gated chloride channels (GluCl)
Ivermectin 400 µg/kg	Ivermectin 400 µg/kg	Assistance Publique - Hôpitaux de Paris	phase 3	Macrocyclic lactone antiparasitic	Glutamate-gated chloride channels (GluCl)
Soolantra® Ivermectin cream 1%	Soolantra® Ivermectin cream 1%	Zydus Worldwide DMCC	phase 3	Macrocyclic lactone antiparasitic / anti-inflammatory	Glutamate-gated chloride channels; innate immune modulators

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrocyclic lactone antiparasitic class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Lihir Medical Centre · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivermectin on Day 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-on-day-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing